<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BRIMONIDINE TARTRATE - brimonidine tartrate solution </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<br><p class="First">Brimonidine Tartrate Ophthalmic Solution, 0.15% (1.5 mg 
brimonidine tartrate per mL equivalent to 1.0 mg brimonidine free base per mL) 
is a relatively selective alpha-2-adrenergic agonist for ophthalmic use. The 
chemical name of brimonidine tartrate is 5-bromo-6-(2-imidazolidinylideneamino) 
quinoxaline L-tartrate. It is an off-white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow powder. It has a 
molecular weight of 442.24 as the tartrate salt, and is both soluble in water 
(1.5 mg/mL) and in the product vehicle (3.0 mg/mL) at pH 7.2. The structural 
formula is:<img alt="image of chemical structure and formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc1785c5-1448-4791-9868-2fbbc8703b3b&amp;name=brimonidine-tartrate-01.jpg"></p>
<p>In solution, Brimonidine Tartrate Ophthalmic Solution, 0.15% has a clear, 
greenish-yellow color. It has an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of 250 - 350 mOsmol/kg and a pH of 
6.6-7.4.</p>
<p>Each mL of Brimonidine Tartrate Ophthalmic Solution, 0.15% contains: <span class="Bold">Active ingredient: </span>brimonidine tartrate 0.15% (1.5 mg/mL) 
<span class="Bold">Inactives: </span>povidone; boric acid; sodium borate; calcium 
chloride; magnesium chloride; potassium chloride; mannitol; sodium chloride; 
POLYQUAD* 0.001% (0.01 mg/mL); purified water; with hydrochloric acid and/or 
sodium hydroxide to adjust pH.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>Mechanism of Action: <p>Brimonidine Tartrate Ophthalmic Solution, 0.15% is an alpha-2 
adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring 
at two hours post-dosing. Fluorophotometric studies in animals and humans 
suggest that brimonidine tartrate has a dual mechanism of action by reducing 
aqueous humor production and increasing uveoscleral outflow.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pharmacokinetics: <p>In a pharmacokinetic study, 14 healthy subjects (4 males and 
10 females) received a single topical ocular administration of Brimonidine 
Tartrate Ophthalmic Solution, 0.15%, one drop per eye. The peak plasma 
concentrations (C<span class="Sub">max</span>) and AUC<span class="Sub"> 
0-inf</span> were 73 ± 19 pg/mL and 375 ± 89 pg•hr/mL, respectively. T<span class="Sub">max</span> was 1.7 ± 0.7 hours after dosing. The systemic half-life 
was approximately 2.1 hours.</p>
<p>Brimonidine is metabolized primarily by the liver. <span class="Italics">In 
vitro </span>metabolism data from human microsomal fractions and liver slices 
indicate that brimonidine undergoes extensive hepatic metabolism.</p>
<p>Urinary excretion is the major route of elimination of brimonidine and its 
metabolites. Approximately 87% of an orally administered radioactive dose of 
brimonidine was eliminated within 120 hours, with 74% of the radioactivity 
recovered in the urine.</p>
<p><span class="Italics">Special Populations</span></p>
<p>Brimonidine Tartrate Ophthalmic Solution, 0.15% has not been studied in 
patients with hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Because of the low systemic drug 
exposure following topical ocular administration of Brimonidine Tartrate 
Ophthalmic Solution, 0.15%, no dose adjustment is necessary when treating 
patients with hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Clinical Evaluations: <p>Elevated IOP presents a major risk factor in glaucomatous field 
loss. The higher the level of IOP, the greater the likelihood of optic nerve 
damage and visual field loss. Brimonidine tartrate has the action of lowering 
intraocular pressure with minimal effect on cardiovascular and pulmonary 
parameters.</p>
<p>A clinical study was conducted to evaluate the safety and efficacy of 
Brimonidine Tartrate Ophthalmic Solution, 0.15% compared to Alphagan® P** 
administered three-times-daily in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or ocular 
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The results indicated that Brimonidine Tartrate Ophthalmic 
Solution, 0.15% is equivalent in IOP-lowering effect to Alphagan® P (brimonidine 
tartrate ophthalmic solution), 0.15%, and effectively lowers IOP in patients 
with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> by 2 - 6 mm Hg.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Brimonidine Tartrate Ophthalmic Solution, 0.15% is indicated for the lowering of 
intraocular pressure in patients with open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> or ocular 
<span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Brimonidine Tartrate Ophthalmic Solution, 0.15% is contraindicated in patients 
with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to brimonidine tartrate or any component of this 
medication. It is also contraindicated in patients receiving monoamine oxidase 
(MAO) inhibitor therapy.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-5"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>General: <p class="First">Although Brimonidine Tartrate Ophthalmic Solution, 0.15% had 
minimal effect on the blood pressure of patients in clinical studies, caution 
should be exercised in treating patients with severe cardiovascular disease.</p>
<p>Brimonidine Tartrate Ophthalmic Solution, 0.15% has not been studied in 
patients with hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; caution should be used in treating 
such patients.</p>
<p>Brimonidine Tartrate Ophthalmic Solution, 0.15% should be used with caution 
in patients with <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, cerebral or coronary insufficiency, Raynaud's 
phenomenon, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, or <span class="product-label-link" type="condition" conceptid="312939" conceptname="Thromboangiitis obliterans">thromboangiitis obliterans</span>. Patients 
prescribed IOP-lowering medication should be routinely monitored for IOP.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Information for Patients: <p>As with other drugs in this class, Brimonidine Tartrate 
Ophthalmic Solution, 0.15% may cause <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and/or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> in some patients. 
Patients who engage in hazardous activities should be cautioned of the potential 
for a decrease in mental alertness.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Drug Interactions: <p>Although specific drug interaction studies have not been 
conducted with Brimonidine Tartrate Ophthalmic Solution, 0.15%, the possibility 
of an additive or potentiating effect with CNS depressants (alcohol, 
barbiturates, opiates, sedatives, or anesthetics) should be considered. Alpha-2 
agonists, as a class, may reduce pulse and blood pressure. Caution in using 
concomitant drugs such as beta-blockers (ophthalmic and systemic), 
anti-hypertensives and/or cardiac glycosides is advised.</p>
<p>Tricyclic antidepressants have been reported to blunt the hypotensive effect 
of systemic clonidine. It is not known whether the concurrent use of these 
agents with Brimonidine Tartrate Ophthalmic Solution, 0.15% in humans can 
interfere with its IOP-lowering effect. No data on the level of circulating 
catecholamines after Brimonidine Tartrate Ophthalmic Solution, 0.15% 
administration are available. Caution, however, is advised in patients taking 
tricyclic antidepressants, which can affect the metabolism and uptake of 
circulating amines.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, and Impairment of 
Fertility: <p>No compound-related carcinogenic effects were observed in either 
mice or rats following a 21-month and a 24-month study, respectively. In these 
studies, dietary administration of brimonidine tartrate at doses up to 
2.5 mg/kg/day in mice and 1.0 mg/kg/day in rats achieved 60 and 50 times, 
respectively, the plasma drug concentration estimated in humans treated with one 
drop of Brimonidine Tartrate Ophthalmic Solution, 0.15% into both eyes.</p>
<p>Brimonidine tartrate was not mutagenic or cytogenic in a series of <span class="Italics">in vitro </span>and <span class="Italics">in vivo </span>studies 
including the Ames test, chromosomal aberration assay in Chinese hamster ovary 
(CHO) cells, a host-mediated assay and cytogenic studies in mice, and dominant 
lethal assay.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pregnancy: Teratogenic Effects: Pregnancy Category: B 
<p>Reproductive studies performed in rats and rabbits with oral 
doses of 0.66 mg base/kg revealed no evidence of harm to the fetus due to 
Brimonidine Tartrate Ophthalmic Solution, 0.15%. Dosing at this level produced 
an exposure in rats and rabbits that is 80 and 40 times higher than the exposure 
seen in humans, respectively.</p>
<p>There are no adequate and well-controlled studies in pregnant women. In 
animal studies, brimonidine crossed the placenta and entered into the fetal 
circulation to a limited extent. Brimonidine Tartrate Ophthalmic Solution, 0.15% 
should be used during pregnancy only if the potential benefit to the mother 
justifies the potential risk to the fetus.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Nursing Mothers: <p>It is not known whether this drug is excreted in human milk. In 
animal studies, brimonidine tartrate was excreted in breast milk. A decision 
should be made whether to discontinue nursing or to discontinue the drug, taking 
into account the importance of the drug to the mother.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pediatric Use: <p>In a well-controlled clinical study conducted in pediatric 
<span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> patients (ages 2 to 7 years) the most commonly observed adverse events 
with brimonidine tartrate ophthalmic solution 0.2% dosed three-times-daily were 
<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (50%-83% in patients ages 2 to 6 years) and decreased alertness. In 
pediatric patients 7 years of age or older (&gt;20 kg), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> appears to 
occur less frequently (25%). Approximately 16% of patients on brimonidine 
tartrate ophthalmic solution discontinued from the study due to <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<p>The safety and effectiveness of brimonidine tartrate ophthalmic solution have 
not been studied in pediatric patients below the age of 2 years. Brimonidine 
tartrate ophthalmic solution is not recommended for use in pediatric patients 
under the age of 2 years. (Also refer to <span><a href="#splSectionAdverseReactions">ADVERSE REACTIONS</a></span> section.)</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Geriatric Use: <p>No overall differences in safety or effectiveness have been 
observed between elderly and other adult patients.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse events occurring in approximately 10-20% of the subjects 
included: <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>, and eye pruritis.</p>
<p>Adverse events occurring in approximately 5-9% of the subjects included: 
<span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>, conjunctival folliculosis, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, ocular allergic 
reaction, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">oral dryness</span>, and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span>.</p>
<p>Events occurring in approximately 1-4% of subjects included: allergic 
reaction, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="374347" conceptname="Blepharoconjunctivitis">blepharoconjunctivitis</span>, 
<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="380117" conceptname="Conjunctival edema">conjunctival edema</span>, 
<span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">conjunctival hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, 
<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">epiphora</span>, <span class="product-label-link" type="condition" conceptid="4080696" conceptname="Discharge from eye">eye discharge</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">eye dryness</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, eye 
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>, eyelid <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, follicular 
<span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, foreign body sensation, <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorder</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, 
<span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">joint disorder</span>, 
<span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, lid disorder, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, 
<span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>, superficial punctate 
<span class="product-label-link" type="condition" conceptid="436695" conceptname="Band-shaped keratopathy">keratopathy</span>, tearing, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>, <span class="product-label-link" type="condition" conceptid="4202518" conceptname="Vitreous detachment">vitreous detachment</span>, vitreous 
disorder, <span class="product-label-link" type="condition" conceptid="4034681" conceptname="Vitreous floaters">vitreous floaters</span>, and worsened visual acuity.</p>
<p>The following events were reported in less than 1% of subjects: corneal 
erosion, <span class="product-label-link" type="condition" conceptid="4171214" conceptname="Nasal mucosa dry">nasal dryness</span>, and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>.</p>
<p>The following events have been identified during post-marketing use of 
brimonidine tartrate ophthalmic solutions in clinical practice. Because they are 
reported voluntarily from a population of unknown size, estimates of frequency 
cannot be made. The events, which have been chosen for inclusion due to either 
their seriousness, frequency of reporting, possible causal connection to 
brimonidine tartrate ophthalmic solutions, or a combination of these factors, 
include: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>; <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>; <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (including <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, eyelid 
pruritis, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and vasodilation); and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, 
<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> have been reported in 
infants receiving brimonidine tartrate ophthalmic solutions.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-7"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No information is available on overdosage in humans. Treatment of an oral 
<span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> includes supportive and symptomatic therapy; a patent airway should be 
maintained.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is one drop of Brimonidine Tartrate 
Ophthalmic Solution, 0.15% in the affected eye(s) three-times-daily, 
approximately 8 hours apart.</p>
<p>Brimonidine Tartrate Ophthalmic Solution, 0.15% may be used concomitantly 
with other topical ophthalmic drug products to lower intraocular pressure. If 
more than one topical ophthalmic product is being used, the products should be 
administered at least 5 minutes apart.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Brimonidine Tartrate Ophthalmic Solution, 0.15% is supplied 
sterile in opaque white LDPE plastic bottles and natural tips with purple 
polypropylene caps as follows:</p>
<p>10 mL in 10 mL bottle NDC 54868-6094-0</p>
<p><br></p>
<p><span class="Bold">Storage: </span>Store at 15°-25° C (59° - 77°F).</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Distributed by:</span></p>
<p>Falcon Pharmaceuticals, Ltd.</p>
<p>Fort Worth, Texas 76134</p>
<p><span class="Bold">Manufactured by:</span></p>
<p>Alcon Laboratories, Inc.</p>
<p>Fort Worth, Texas 76134</p>
<p>Printed in USA</p>
<p>*POLYQUAD is a registered trademark of Alcon Research, Ltd.</p>
<p>**ALPHAGAN P is a registered trademark of Allergan, Inc.</p>
<p><span class="Bold">349040-1008</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-10"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">Brimonidine Tartrate Opthalmic Solution</p>
<div class="Figure"><img alt="image of Brimonidine Tartrate package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bc1785c5-1448-4791-9868-2fbbc8703b3b&amp;name=Brimonidine%20Tartrate%20package%20label.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BRIMONIDINE TARTRATE 		
					</strong><br><span class="contentTableReg">brimonidine tartrate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-6094(NDC:61314-144)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BRIMONIDINE TARTRATE</strong> (BRIMONIDINE) </td>
<td class="formItem">BRIMONIDINE TARTRATE</td>
<td class="formItem">1.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BORATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-6094-0</td>
<td class="formItem">10 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021764</td>
<td class="formItem">12/22/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cac38eb9-dc7f-4ce6-99b6-c65d10caf2f8</div>
<div>Set id: bc1785c5-1448-4791-9868-2fbbc8703b3b</div>
<div>Version: 1</div>
<div>Effective Time: 20100112</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
